Feasibility and efficacy of 223Ra-dichloride in treatment of bone metastases in patients with castration-refractory prostate cancer (mCRPC)

被引：0
|
作者：
Mazzarri, S. [1 ]
Boni, G. [1 ]
Borso, E. [2 ]
Galli, L. [3 ]
Farnesi, A. [3 ]
Betti, F. [1 ]
Antonacci, L. [1 ]
Traino, A. [4 ]
Ricci, S. [3 ]
Volterrani, D. [1 ]
机构：
[1] Univ Hosp Pisa, Reg Ctr Nucl Med, Pisa, Italy
[2] SantAndrea Hosp La Spezia, Div Nucl Med, La Spezia, Italy
[3] Univ Hosp Pisa, Div Oncol, Pisa, Italy
[4] Univ Hosp, Sect Med Phys, Hlth Phys Unit, Pisa, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP136
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [11] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [12] 223Ra-Dichloride therapy in Prostate Cancer: Portuguese reality
    Monteiro, L.
    Carvalho, A. L.
    Vieira, D.
    Costa, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S761 - S761
  • [13] 223Ra-dichloride: Prognostic value of Baseline Quality of Life in mCRPC patients candidates to treatment
    Frantellizzi, V.
    De Feo, M.
    De Angelis, C.
    De Vincentis, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S647
  • [14] The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer
    Murray, Iain
    Chittenden, Sarah J.
    Denis-Bacelar, Ana M.
    Hindorf, Cecilia
    Parker, Christopher C.
    Chua, Sue
    Flux, Glenn D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (11) : 1832 - 1844
  • [15] The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer
    Iain Murray
    Sarah J. Chittenden
    Ana M. Denis-Bacelar
    Cecilia Hindorf
    Christopher C. Parker
    Sue Chua
    Glenn D. Flux
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1832 - 1844
  • [16] Analysis of Clinical parameters for the outcame prediction of mCRPC patients treated with 223Ra-dichloride
    Frantellizzi, V.
    Follacchio, G. A.
    Sollaku, S.
    Lazri, J.
    Farcomeni, A.
    Pacilio, M.
    Liberatore, M.
    Monteleone, F.
    De Vincentis, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S133 - S133
  • [17] First experiences in clinical routine using Ra-223 dichloride for treatment of bone metastases in patients with castration-resistent prostate cancer
    Marx, M.
    Zuhayra, M.
    Zhao, Y.
    Winkler, C.
    Bothe, K.
    Luetzen, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S548 - S548
  • [18] Dosimetry, imaging and administration of radium (Ra) 223 dichloride in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Flux, Glenn
    Chittenden, Sarah
    Pratt, Brenda
    Hindorf, Cecilia
    Parker, Chris
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 : S51 - S51
  • [19] Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report
    De Vincentis, Giuseppe
    Follacchio, Giulia Anna
    Frantellizzi, Viviana
    Liberatore, Mauro
    Monteleone, Francesco
    Cortesi, Enrico
    CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : E529 - E533
  • [20] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hiroji
    Uemura, Hirotsugu
    Matsubara, Nobuaki
    Kinuya, Seigo
    Hosono, Makoto
    Yajima, Yoko
    Doi, Toshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 954 - 963
12345